Neuraxis, INC reported the three months ended March 31, 2026 results: revenue approximately $1.6 million.
“On April 21, 2026, Neuraxis, Inc. (the “Company”), issued disclosure that, on a preliminary unaudited basis, the Company expects its cash and cash equivalents to be approximately $7.1 million as of March 31, 2026. The Company expects its net sales to be approximately $1.6 million for the three months ended March 31, 2026, as compared to approximately $0.9 million for the three months ended March 31, 2025.”
Dr. Gil Aharon was appointed as Director at Neuraxis, INC.
“the Board appointed Dr. Aharon to the Board, effective January 1, 2025.”
Dan Clarence was terminated as Chief Operating Officer at Neuraxis, INC.
“On April 10, 2024, the employment of Dan Clarence, Chief Operating Officer of NeurAxis, Inc. (the "Company"), terminated effective immediately.”
Earnings Releases
Neuraxis, INC reported the year ended December 31, 2023 results: revenue $2.5 million.
“medical space well, I believe we are well positioned to execute our business plan in 2024. ” Fourth Quarter and Fiscal Year 2023 Financial Results Revenue in fiscal year 2023 of $2.5 million was down 8.4% compared to $2.7 million in fiscal year 2022. The decrease was primarily due to fewer shipments to certain customers as they manage th”
Auditor Changes
Neuraxis, INC reported that prior financial statements should not be relied upon.
“On April 4, 2024, the Board of Directors (the “Board”) of the Company, upon the recommendation of the Audit Committee of the Board and after discussion with management, concluded that the Company’s previously issued unaudited financial statements as of and for the three and nine months period ended September 30, 2023 filed with the Securities and Exchange Commission on November 20, 2023, should no longer be relied upon and should be restated due to the identification of a material accounting error.”
Material Agreements
Neuraxis, INC amended SPA with Flagstaff International, LLC valued at $5 million (effective 2024-03-22).
“On March 22, 2024, the Company and Flagstaff entered into the third amendment to the SPA (the “Amendment”) to increase the investment amount from $3 million to $5 million”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.